Argenta in discovery collaboration with Corcept
UK-based Argenta Discovery has entered into a comprehensive, multi-year collaboration with Corcept Therapeutics, of California, for the discovery and optimisation of a second generation drug candidate within one of Corcept's psychiatric disorder programmes.
UK-based Argenta Discovery has entered into a comprehensive, multi-year collaboration with Corcept Therapeutics, of California, for the discovery and optimisation of a second generation drug candidate within one of Corcept's psychiatric disorder programmes.
Under the terms of the collaboration, Argenta and Corcept scientists will work closely together in an interdisciplinary team to fully exploit the integration of biology and chemistry.
Dr Anthony Baxter, ceo of Argenta, said: 'We are pleased to announce this alliance with Corcept, which illustrates the global attraction of our contract services. This collaboration enables Argenta to deploy its full armoury of capabilities in chemistry, screening and eADME in an integrated approach to lead discovery and optimisation.
'We believe this agreement also highlights the value companies are increasingly placing on genuine industry experience when choosing a partner in drug discovery.'